Generic Eliquis Availability

Eliquis is a brand name of apixaban, approved by the FDA in the following formulation(s):

ELIQUIS (apixaban - tablet;oral)

Has a generic version of Eliquis been approved?

No. There is currently no therapeutically equivalent version of Eliquis available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Eliquis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Nitrogen containing heterobicycles as factor Xa inhibitors
    Patent 6,413,980
    Issued: July 2, 2002
    Inventor(s): John M.; Fevig & Joseph; Cacciola & Charles G.; Clark & Qi; Han & Patrick Yuk Sun; Lam & Donald J.P.; Pinto & James R.; Pruitt & Mimi L.; Quan & Karen A.; Rossi
    Assignee(s): Bristol-Myers Squibb Pharma Company
    The present application describes nitrogen containing heterobicyclics and derivatives thereof, or pharmaceutically acceptable salt forms thereof, which are useful as inhibitors of factor Xa.
    Patent expiration dates:
    • December 22, 2019
      ✓ 
      Patent use: REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • December 22, 2019
      ✓ 
      Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • December 22, 2019
      ✓ 
      Patent use: TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • December 22, 2019
      ✓ 
      Patent use: TREATMENT OF PULMONARY EMBOLISM (PE)
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
    Patent 6,967,208
    Issued: November 22, 2005
    Inventor(s): Pinto; Donald J. P. & Quan; Mimi L. & Orwat; Michael J. & Li; Yun-Long & Han; Wei & Qiao; Jennifer X. & Lam; Patrick Y. S. & Koch; Stephanie L.
    Assignee(s): Bristol-Myers Squibb Pharma Company
    The present application describes lactam-containing compounds and derivatives thereof of Formula I: or pharmaceutically acceptable salt forms thereof, wherein ring P, if present is a 5-7 membered carbocycle or heterocycle and ring M is a 5-7 membered carbocycle or heterocycle. Compounds of the present invention are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa.
    Patent expiration dates:
    • February 3, 2023
      ✓ 
      Patent use: REDUCING THE RISK OF STROKE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • February 3, 2023
      ✓ 
      Patent use: REDUCING THE RISK OF STROKE AND SYSTEMIC EMBOLISM
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • February 3, 2023
      ✓ 
      Patent use: TREATMENT OF PULMONARY EMBOLISM (PE)
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • February 3, 2023
      ✓ 
      Patent use: TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • February 3, 2023
      ✓ 
      Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • February 3, 2023
      ✓ 
      Patent use: PROPHYLAXIS OF PULMONARY EMBOLISM
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • February 3, 2023
      ✓ 
      Patent use: PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT)
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • March 3, 2017 - PROPHYLAXIS OF DEEP VEIN THROMBOSIS (DVT) WHICH MAY LEAD TO PULMONARY EMBOLISM (PE), IN ADULT PATIENTS WHO HAVE UNDERGONE HIP OR KNEE REPLACEMENT
    • August 21, 2017 - TREATMENT OF PULMONARY EMBOLISM
    • August 21, 2017 - INDICATED TO REDUCE THE RISK OF RECURRENT DEEP VEIN THROMBOSIS (DVT) AND PULMONARY EMBOLISM (PE) FOLLOWING INITIAL THERAPY
    • August 21, 2017 - INDICATED FOR THE TREATMENT OF DEEP VEIN THROMBOSIS (DVT)
    • December 28, 2017 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide
(web5)